Quad-peptide mechanism. Synergy cascade. Dosing rationale. Written for women who want the receipts.
Four Peptides. Four Mechanisms.
KPV is a tripeptide derived from the C-terminal fragment of alpha-melanocyte stimulating hormone (α-MSH). Its primary mechanism is melanocortin receptor 1 (MC1R) agonism, which drives a potent anti-inflammatory response — not through immunosuppression, but through active immune down-regulation at sites of tissue stress. It reduces TNF-α, IL-1β, and IL-6 signaling in local tissue microenvironments. It also has direct anti-microbial action against Staphylococcus aureus and other gram-positive pathogens.
Perimenopause is characterized by a documented increase in systemic inflammatory tone — a condition sometimes called "inflammaging" in the longevity literature. Estrogen has broad anti-inflammatory effects; as it declines, inflammatory cytokines rise across the board. Elevated IL-6 alone is associated with increased muscle catabolism, reduced collagen synthesis, and accelerated bone density loss. KPV addresses this upstream — suppressing the inflammatory baseline that would otherwise undermine whatever the other three peptides are trying to accomplish. Without this step, the repair signals from GHK-Cu, BPC-157, and TB-500 are working against a headwind.
J Cell Physiol. 2009; Nicoletti F et al. — MC1R-mediated anti-inflammatory effects of KPV in human dermal tissue. Peptides. 2012; Velders M et al. — α-MSH fragments and their anti-cytokine activity in models of chronic inflammation. KPV is also well-characterized in the context of IBD and inflammatory skin disorders.
GHK-Cu is a naturally occurring copper-binding tripeptide present in human plasma at concentrations of 10–200 ng/mL, declining with age. The copper ion is not incidental — it is the active co-factor that enables the peptide's biological activity. GHK-Cu binds copper with picomolar affinity, forming a complex that enters cells via the copper transporter (CTR1) and activates a suite of tissue repair genes. It stimulates collagen, elastin, and glycosaminoglycan synthesis; promotes fibroblast proliferation; and accelerates wound closure through both VEGF upregulation (angiogenesis) and direct fibroblast activation.
GHK-Cu's natural decline is one of the least-discussed aspects of perimenopausal tissue change — yet its effects are profound. Skin thinning, increased fragility, slower wound healing, and reduced skin elasticity all track with declining GHK-Cu activity. The additional wrinkle (literally) is that estrogen supports copper metabolism; as estrogen falls, copper bioavailability shifts, impairing the very pathway GHK-Cu relies on. This is why topical copper peptides have become a significant category in clinical dermatology — but oral/ injectable supplementation directly addresses the systemic collagen decline that topical products cannot reach.
J Invest Dermatol. 2012; Pickart L et al. — GHK-Cu stimulates collagen and glycosaminoglycan synthesis in human skin fibroblasts. Chem Biol Drug Des. 2015; Barnham K et al. — Copper-GHK interactions and their role in tissue repair. GHK-Cu has been in clinical dermatology use since the 1970s; its mechanism is among the most thoroughly characterized of any peptide in the literature.
BPC-157 is a pentadecapeptide — 15 amino acids — originally isolated from human gastric juice, where it functions as a mucosal protective compound. Its systemic effects extend far beyond the gut. BPC-157 promotes angiogenesis (new blood vessel formation) through VEGF pathway upregulation, stabilizes the gut-brain axis, supports growth hormone receptor expression, and has documented protective effects against NSAID-induced intestinal damage. In animal models, it accelerates wound healing, tendon repair, and bone healing through what appears to be a unifying mechanism: restoring or amplifying cellular communication disrupted by injury or chronic stress.
The gut is disproportionately affected by perimenopausal hormonal shifts. Estrogen maintains gut barrier integrity through estrogen receptor-β (ER-β) signaling in intestinal epithelial cells; as estrogen falls, tight junction proteins (claudin-1, occludin, ZO-1) become less well regulated. The result is increased intestinal permeability — colloquially "leaky gut" — which allows endotoxins to pass into systemic circulation, driving further inflammation. BPC-157 is one of the few peptides with robust evidence for gut barrier stabilization. Combined with its vascular support, it effectively rebuilds the delivery infrastructure that the other peptides need to reach their target tissues.
World J Gastroenterol. 2019; Sikiric P et al. — BPC-157 and its gastroprotective and healing effects. Pharmaceuticals. 2021; Gwyer D et al. — BPC-157: mechanism of action and therapeutic applications. VEGF upregulation and angiogenesis effects documented in multiple rodent models; gut barrier data replicated in multiple independent labs.
TB-500 is the first four amino acids of the 43-amino-acid Thymosin Beta-4 protein. The full Tβ4 protein is found in virtually every human cell and is heavily involved in cell migration, differentiation, and tissue repair. The TB-500 fragment retains the primary regenerative activity while being a more tractable peptide for dosing purposes. Its primary mechanism is actin regulation — TB-500 sequesters G-actin (globular actin), maintaining a pool of monomeric actin available for polymerization into F-actin filaments, which are the structural core of the cellular cytoskeleton. This has cascade effects on cell motility, wound closure, and tissue flexibility.
Tissue flexibility is one of the quietest casualties of perimenopause. Skin loses elasticity not just because collagen declines — it loses the ability to remodel in response to daily micro-stress. Muscles and tendons take longer to recover. The fascial system — the connective tissue matrix that runs throughout the body — becomes denser and less compliant. TB-500 addresses this at the most fundamental structural level: the cytoskeleton that governs how every cell in your body moves, responds to mechanical stress, and rebuilds itself after damage.
FASEB J. 2004; Smart N et al. — Thymosin β4 and tissue repair. J Mol Cell Cardiol. 2011; Crockford D et al. — TB4 and TB-500: therapeutic potential in tissue repair. Note: much of the high-quality animal data on Tβ4 remains in the preclinical literature; human clinical data is less extensive and this is disclosed in consultation.
The Cascade
No single peptide addresses the full scope of perimenopausal tissue decline. KLOW is designed around a sequenced cascade — each peptide clearing the path for the next, so the repair mechanisms can actually land.
The cascade begins with KPV. Before any repair mechanism can work, the inflammatory baseline must be addressed. KPV suppresses NF-κB and reduces pro-inflammatory cytokine signaling — creating a cleaner microenvironment where the subsequent peptides can engage their receptors without competing against a pro-inflammatory tide.
With inflammation suppressed, GHK-Cu can engage its copper-dependent repair pathways unobstructed. Collagen synthesis, elastin production, and glycosaminoglycan deposition can proceed at full capacity. The VEGF upregulation that GHK-Cu triggers also begins building the vascular infrastructure that BPC-157 will expand further.
BPC-157 runs concurrently with GHK-Cu, amplifying and stabilizing it. Its gut barrier stabilization ensures that the intestinal lining — increasingly compromised in perimenopause — is repaired and tightened. Its angiogenesis amplification (beyond what GHK-Cu started) creates a robust vascular network that distributes all four peptides throughout the body's tissues effectively. GH receptor upregulation amplifies any residual growth hormone in the system.
TB-500 activates in the later phase of the cycle (weeks 5–8), as the tissue substrate built by KPV, GHK-Cu, and BPC-157 is ready to be remodeled. Actin cytoskeleton regulation enables the tissue architecture that collagen synthesis produced to actually integrate — flexibility is restored, not just built. The fascial system, which has become increasingly dense and non-compliant, remodels with restored cellular plasticity.
Calms inflammatory tone. Clears tissue terrain.
Activates collagen synthesis. Drives angiogenesis.
Stabilizes gut barrier. Amplifies vascular network.
Actin remodeling. Flexibility. Systemic integration.
Dosing Rationale
Peptide receptors, like all receptor systems, can become desensitized with continuous agonist exposure — a phenomenon well documented in growth hormone receptor (GHR) signaling and melanocortin receptor systems. The 2-week washout period is not a rest period in the casual sense. It is the mechanism by which receptor sensitivity is maintained: after approximately 8 weeks of continuous agonism, receptor internalization (internalization of the receptor protein into the cell) begins to outpace receptor resynthesis. The 2-week off period allows the full receptor complement to re-express on the cell surface before the next cycle begins.
Each peptide in KLOW has a distinct pharmacokinetic profile that informs the dosing schedule. GHK-Cu has a circulating half-life of approximately 24–48 hours due to its copper-bound complex stability; this supports less frequent dosing without loss of effect. BPC-157 has a notably long half-life for a peptide of its size — estimated at 4–6 hours systemically, but it accumulates in tissues with repeated dosing, which is why the therapeutic effect continues to build through week 8. KPV and TB-500 both have shorter half-lives, requiring more consistent dosing throughout the cycle.
Each 8-week active cycle requires 3.5 vials. This number is derived from the 10-week total cycle (8 on + 2 off) divided by the vial duration (~2.85 weeks/vial), rounding to the nearest half-vial to accommodate the washout period's reduced dosing requirements. The 0.5-vial buffer accounts for variability in individual metabolism and ensures complete coverage through the final days of the active phase. Physician review at week 4 determines whether any adjustment to the cycle is appropriate before the second half begins.
At the 8-on/2-off cadence, a year accommodates approximately 5.5 complete cycles. This is the frame within which outcomes are assessed. Most women see meaningful tissue-level changes by cycle 2–3; some notice improvements earlier. Clinical review between cycles determines whether to continue, adjust dose, or extend the washout period based on outcomes observed.
Physician Guardrails
KLOW is Eterna Femme's most complex protocol. Its multi-peptide nature, the interactions between GHK-Cu's copper metabolism and the body's inflammatory signaling, and the dosing sequence across an 8-week cycle require physician oversight — not as a formality, but as clinical practice. Here is what that means in practice.
A comprehensive health intake is required before KLOW is initiated. This is not a questionnaire — it is a clinical review of medical history, current medications, supplement use, and relevant lab work. The intake physician evaluates each candidate against a defined list of contraindications before the protocol begins.
Active malignancy or a history of hormone-sensitive cancers; active anticoagulant therapy; copper-restricted therapeutic regimens (e.g., Wilson's disease management); active autoimmune conditions not stable for at least 12 months; pregnancy or active planning for pregnancy. Women with severe liver or kidney impairment are also excluded pending additional evaluation.
Week 4 mid-cycle clinical check-in: the physician reviews symptom response, any adverse effects, and adherence. Adjustments to dose or timing are made at this point when indicated. End-of-cycle review: outcomes assessment, washout guidance, and decision on next cycle candidacy. Women on the 3-cycle or 6-cycle plans have ongoing clinical support throughout all active cycles.
Any new or worsening symptoms, any new medications or supplements, any lab results obtained outside of Eterna Femme, any medical procedures or hospitalizations. The care team is accessible via secure messaging throughout the cycle — not just at the scheduled check-ins.
KLOW is not a self-directed supplement stack. Every woman who enters the protocol has been evaluated by a licensed prescribing physician and has ongoing clinical support throughout the cycle.
This is what it means when Eterna Femme says "physician-guided." Not a disclaimer. A practice.
Continue Exploring
Pricing, cycle structure, and tier details for the full quad-peptide protocol. From $220/cycle.
View KLOW Overview →Begin your KLOW intake. A licensed prescribing physician will review your profile and determine candidacy.
Start Consultation →The founding thesis behind Eterna Femme — why peptides, why women 40+, why physician-guided matters.
Read Our Approach →